Plain-English translation of NCT06743945 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a new medication combination called can effectively treat transformed lymphoma — an aggressive form of lymphoma that develops when a slower-growing lymphoma transforms into a faster-growing cancer. Right now, there is no standard treatment for this condition, so this study aims to find out if this medication combination works and is safe for patients.
Patients with transformed lymphoma currently have no established, standard treatment option. This trial exists to evaluate whether this medication could become a new first-line therapy — a first-choice treatment — for people newly diagnosed with this serious condition.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the new medication combination as your first treatment for transformed lymphoma. The study will monitor how well the treatment works, track any side effects, and check your blood counts, organ function, and overall response to the medication. You will be followed at a medical center experienced in treating lymphoma, with regular visits and tests to ensure the treatment is safe and effective for you.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fudan University
Enrollment target
~20 participants
Started
February 2025
Primary completion
December 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yizhen Liu, M.D., Ph.D.
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.